DOSEGUY

1,4-DMAA

guinea pig

Also seen as: 1,4-dimethylamylamine, 1,4-dimethylpentylamine, 14-DMAA

The Dose Guy’s verdict
Sep 1, 2026
2 sources

A positional isomer of 1,3-DMAA sold in supplements after the original got banned, with zero human safety or efficacy data of its own. Not one pharmacokinetic study, not one hemodynamic measurement, not one trial of any kind. You are buying the assumption that it acts like its better-studied sibling, but nobody has verified that in a person. Running a compound with no human data and no dose consistency is a pure gamble.

Would I take it?Caution, you are the experiment.

What it is

The FDA pulled 1,3-DMAA from the market after cardiac events and deaths. The supplement industry’s answer was not to stop selling stimulant amines but to shift one methyl group and sell the isomer instead. That is the entire origin story of 1,4-DMAA: a structural tweak to dodge a regulatory action, not a drug designed for a purpose.

The two compounds are isomeric heptylamines, meaning they share a molecular formula but differ in where a branch sits on the carbon chain. Whether that difference matters for potency, safety, or duration is unknown because nobody has studied 1,4-DMAA in a person. The assumption in the supplement world is that it acts roughly like its isomer, a sympathomimetic with stimulant and appetite-suppressing effects, and the assumption may be right. But “probably similar to the one that killed people” is not a safety case.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The published literature on 1,4-DMAA is entirely analytical: labs measuring what is in the pills, not what the pills do to people.

In six supplement brands, measured 1,4-DMAA quantities ranged from 21 plus or minus 11 mg to 94 plus or minus 48 mg per serving. One product combined it with 1,3-DMAA in the same capsule.Clin Toxicol 2018 · lab analysis
Among 17 deterenol-labeled supplements, products contained up to four prohibited stimulants per serving alongside other banned amines.Clin Toxicol 2021 · lab analysis
No human trial of any kind exists for 1,4-DMAA: no pharmacokinetics, no safety study, no efficacy data. The entire human evidence base is zero.as of Aug 2026

Realistic protocols

There is no defensible protocol for a compound with zero human pharmacology. One 2021 survey found 5.3 mg per serving, another in 2018 measured 21 to 94 mg, which tells you how little standardization exists. If you run it, you are guessing the dose, guessing the duration, and guessing the risk, with no reference point from any human study. The only honest advice: skip it. If you want a stimulant, caffeine has decades of human data, and even 1,3-DMAA at least has human PK and known hemodynamic effects.

Side effects

No human side-effect data exists. The assumption is the sympathomimetic profile, borrowed from its isomer:

anecdotalStimulant effects, elevated blood pressure, tremor, and crash, all assumed from 1,3-DMAA and from user reports on multi-ingredient products.
unknownNo human safety study has ever been conducted. The cardiovascular risks of 1,3-DMAA are documented, including fatal cardiac events. Whether this isomer carries the same risks, higher, or lower is genuinely unknown.

Where to buy

No live listings from tracked vendors right now.